login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
SYNDAX PHARMACEUTICALS INC (SNDX) Stock News
NASDAQ:SNDX -
US87164F1057
-
Common Stock
16.24
USD
+0.4 (+2.53%)
Last: 8/22/2025, 8:00:02 PM
16
USD
-0.24 (-1.48%)
After Hours:
8/22/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNDX Latest News, Press Relases and Analysis
All
Press Releases
18 days ago - By: Chartmill
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss
9 days ago - By: Zacks Investment Research
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?
17 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 days ago - By: Yahoo Finance
Citi ups Syndax target, opens ‘upside catalyst watch’
18 days ago - By: The Motley Fool
Syndax (SNDX) Q2 Revenue Jumps 986%
18 days ago - By: Zacks Investment Research
- Mentions:
ABSI
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
19 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
19 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
19 days ago - By: Benzinga
- Mentions:
VRTX
RHP
NVTS
MSA
...
Earnings Scheduled For August 4, 2025
21 days ago - By: Benzinga
Syndax Pharmaceuticals's Earnings: A Preview
25 days ago - By: Zacks Investment Research
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
25 days ago - By: Zacks Investment Research
- Mentions:
JAZZ
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline
25 days ago - By: Zacks Investment Research
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
26 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
26 days ago - By: Syndax Pharmaceuticals, Inc.
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
2 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in June Investor Conferences
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in June Investor Conferences
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
3 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
4 months ago - By: Zacks Investment Research
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
4 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Participation in May Investor Conferences
4 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
4 months ago - By: Syndax Pharmaceuticals, Inc.
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
Please enable JavaScript to continue using this application.